TEVA
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
Research · Nov 4, 2026
Teva (TEVA) Q3 2026 Earnings: AUSTEDO Beats, Destocking Shifts to Q4
Teva's Q3 2026 AUSTEDO revenue of $751 million beat the range implied by prior guidance with no visible destocking; Teva raised three brand outlooks as non-GAAP gross margin hit 58.7%.
Research · Oct 31, 2026
[TEVA] Teva: Q3 2026 Earnings Test AUSTEDO Destocking Before Medicare Price Cap
Teva's Q2 2026 revenue fell 1% to $4.14 billion as US AUSTEDO sales rose 37%; Q3 earnings test whether pre-IRA destocking pushes AUSTEDO below guidance.
Research · Sep 3, 2026
[TEVA] Teva Pharmaceutical Thesis 2026: Austedo Becomes Growth Engine as Turnaround Matures
Teva Pharmaceutical FY25 (Dec 31, 2025) at $17.26B revenue (+4%). NI $1.41B; EPS $1.20 (major turnaround from FY24 -$1.45). Op income flipped from -$303M to +$2.16B. Innovative portfolio: AUSTEDO $2.26B (+35%); UZEDY $191M (+63%); AJOVY $673M (+30%). 3 consecutive years of growth. FY26: revenue $16.4-$16.8B, GM 54.5-55.5%, EPS $2.57-$2.77, FCF $2-$2.4B; AUSTEDO $2.4-$2.55B.